We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Omega-3 Dietary Supplements Fail to Hold Back Mental Decline

By HospiMedica International staff writers
Posted on 27 Jun 2012
A new review suggests that increased consumption of fish oils rich in omega-3 long-chain polyunsaturated fatty acids (omega-3 PUFA) shows no benefit among cognitively healthy older people. More...


Researchers at the London School of Hygiene and Tropical Medicine (United Kingdom) conducted a meta-study involving three trials of omega-3 supplementation in which 3,536 participants--over 60 years of age and cognitively healthy at the start of the study--were randomized to receive extra omega-3 PUFA in their diet or a placebo (such as olive oil). The main outcome measures were new cases of dementia diagnosed during the study period, cognitive decline, side effects, and adherence to the intervention.

The results showed that in two studies, involving 3,221 participants, there was no difference between the omega-3 PUFA and placebo group in mini-mental state examination score at final follow-up. In two studies, involving 1,043 participants, other tests of cognitive function such as word learning, digit span, and verbal fluency showed no beneficial effect of omega-3 PUFA supplementation. Participants in both the intervention and control groups experienced little or no cognitive decline during the studies.
In all three studies, mild gastrointestinal symptoms were the most common side effects, and were reported with equal frequency in treatment and placebo groups. Adherence to the supplementation protocol was high in all trials with on average over 90% of supplements being apparently consumed by trial participants. The study was published online on June 6, 2012, in the Cochrane Database of Systematic Reviews.

“All three studies included in this review were of high methodological quality, and so the findings are unlikely to be due to chance or bias,” concluded lead author Emma Sydenham, MSc, and colleagues. “While cognitive benefits were not demonstrated in this review, consumption of two servings of fish each week, with one being an oily fish such as salmon or sardines, is widely recommended for overall health benefits.”

Oily fish such as salmon, mackerel, herring, and sardines are a rich source of omega-3 PUFA, which are essential for brain development.

Related Links:

London School of Hygiene and Tropical Medicine





Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.